Multiple Sclerosis

Multiple sclerosis (MS) is the most common non-traumatic disabling disease that affects young adults. It is an autoimmune-mediated neurodegenerative condition that primarily impacts the central nervous system. MS is characterized by inflammatory demyelination, which involves the breakdown of the protective myelin sheath around nerve fibers, along with axonal transection. Symptoms of MS typically emerge in individuals aged 20 to 30 and may include unilateral optic neuritis, partial myelitis, sensory disturbances, or brainstem syndromes like internuclear ophthalmoplegia, which develop over several days. 

Mesenchymal stem cells (MSCs) are a type of multipotent cells with notable capabilities for proliferation and self-renewal. They possess immunomodulatory and neuroregenerative properties, making them a potential therapeutic option for various diseases. MSCs can be easily isolated from bone marrow and adipose tissues, and in the case of MS, autologous MSCs derived from the patient themselves can be used, eliminating the risk of rejection. Importantly, using autologous MSCs minimizes safety concerns, as they carry a safer profile without the risk of malignant transformation. This makes MSCs a viable therapy for individuals with MS. 

 

Multiple Sclerosis

Citations and Scientific References

Our medical unit is highly esteemed for partnering globally with fellow researchers on scientific studies and contributing to respected scientific journals.

View References